遗传学在血液系统恶性肿瘤中的当前作用
Current Role of Genetics in Hematologic Malignancies.
作者信息
Prakash Gaurav, Kaur Anupriya, Malhotra Pankaj, Khadwal Alka, Sharma Prashant, Suri Vikas, Varma Neelam, Varma Subhash
机构信息
Clinical Hematology and BMT Division, Department of Internal Medicine, PGIMER, Chandigarh, India.
Medical Geneticist, Sarai Building, Government Medical College, Chandigarh, 160030 India.
出版信息
Indian J Hematol Blood Transfus. 2016 Mar;32(1):18-31. doi: 10.1007/s12288-015-0584-4. Epub 2015 Sep 16.
Abstract
Rapidly changing field of genetic technology and its application in the management of hematological malignancies has brought significant improvement in treatment and outcome of these disorders. Today, genetics plays pivotal role in diagnosis and prognostication of most hematologic neoplasms. The utilization of genetic tests in deciding specific treatment of various hematologic malignancies as well as for evaluation of depth of treatment response is rapidly advancing. Therefore, it is imperative for practitioners working in the field of hemato-oncology to have sufficient understanding of the basic concepts of genetics in order to comprehend upcoming molecular research in this area and to translate the same for patient care.
摘要
基因技术领域的快速发展及其在血液系统恶性肿瘤管理中的应用，给这些疾病的治疗和预后带来了显著改善。如今，遗传学在大多数血液肿瘤的诊断和预后判断中起着关键作用。基因检测在确定各种血液系统恶性肿瘤的具体治疗方案以及评估治疗反应深度方面的应用正在迅速推进。因此，血液肿瘤学领域的从业者必须充分了解遗传学的基本概念，以便理解该领域即将开展的分子研究，并将其转化应用于患者护理。
相似文献
1
Current Role of Genetics in Hematologic Malignancies.遗传学在血液系统恶性肿瘤中的当前作用
Indian J Hematol Blood Transfus. 2016 Mar;32(1):18-31. doi: 10.1007/s12288-015-0584-4. Epub 2015 Sep 16.
2
Building a National Framework for Adolescent and Young Adult Hematology and Oncology and Transition from Pediatric to Adult Care: Report of the Inaugural Meeting of the "AjET" Working Group of the German Society for Pediatric Oncology and Hematology.构建青少年和青年血液学与肿瘤学国家框架以及从儿科护理向成人护理的过渡：德国儿科肿瘤学和血液学协会“AjET”工作组首次会议报告
J Adolesc Young Adult Oncol. 2017 Jun;6(2):194-199. doi: 10.1089/jayao.2016.0075. Epub 2016 Dec 16.
3
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).个性化医学和肿瘤免疫时代临床试验的变化：国际肿瘤学和血液肿瘤学临床试验大会（ICTO 2017）报告。
J Exp Clin Cancer Res. 2017 Dec 28;36(1):192. doi: 10.1186/s13046-017-0668-0.
4
The management of hematologic malignancies during the COVID-19 pandemic.COVID-19 大流行期间血液系统恶性肿瘤的管理。
Expert Opin Pharmacother. 2021 Apr;22(5):565-582. doi: 10.1080/14656566.2020.1849143. Epub 2020 Dec 21.
5
Nanotechnology applications in hematological malignancies (Review).纳米技术在血液系统恶性肿瘤中的应用（综述）
Oncol Rep. 2015 Sep;34(3):1097-105. doi: 10.3892/or.2015.4100. Epub 2015 Jul 2.
6
Palliative care and the hemato-oncological patient: can we live together? A review of the literature.姑息治疗与血液肿瘤患者：能否共存？文献复习。
J Palliat Med. 2010 Aug;13(8):1021-5. doi: 10.1089/jpm.2009.0267.
7
The role of next-generation sequencing in hematologic malignancies.下一代测序在血液系统恶性肿瘤中的作用。
Blood Res. 2024 Mar 6;59(1):11. doi: 10.1007/s44313-024-00010-0.
8
Supportive and palliative care in hemato-oncology: how best to achieve seamless integration and subspecialty development?血液肿瘤学中的支持性和姑息治疗：如何最好地实现无缝整合和亚专科发展？
Ann Hematol. 2021 Mar;100(3):601-606. doi: 10.1007/s00277-020-04386-8. Epub 2021 Jan 3.
9
Diagnosis of invasive fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).血液学和肿瘤学中侵袭性真菌感染的诊断——德国血液学和肿瘤学会（DGHO）传染病工作组（AGIHO）指南
Ann Hematol. 2003 Oct;82 Suppl 2:S141-8. doi: 10.1007/s00277-003-0768-0. Epub 2003 Sep 11.
10
Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders.血液系统恶性肿瘤和良性血液系统疾病的分子方面。
Int J Mol Sci. 2023 Jun 6;24(12):9816. doi: 10.3390/ijms24129816.
引用本文的文献
1
Cytokine-induced killer cells: new insights for therapy of hematologic malignancies.细胞因子诱导的杀伤细胞：恶性血液病治疗的新见解。
Stem Cell Res Ther. 2024 Aug 13;15(1):254. doi: 10.1186/s13287-024-03869-z.
2
Non-invasive prenatal test identifies circulating cell-free DNA chromosomal abnormalities derived from clonal hematopoiesis in aggressive hematological malignancies.非侵入性产前检测可识别源自侵袭性血液恶性肿瘤中克隆性造血的循环无细胞 DNA 染色体异常。
Clin Exp Med. 2024 Apr 5;24(1):69. doi: 10.1007/s10238-024-01313-3.
3
Artificial Intelligence-Assisted Diagnostic Cytology and Genomic Testing for Hematologic Disorders.人工智能辅助诊断细胞学和血液病基因组检测。
Cells. 2023 Jun 30;12(13):1755. doi: 10.3390/cells12131755.
4
The Role of N-Methyladenosine (mA) Methylation Modifications in Hematological Malignancies.N-甲基腺苷（m⁶A）甲基化修饰在血液系统恶性肿瘤中的作用
Cancers (Basel). 2022 Jan 11;14(2):332. doi: 10.3390/cancers14020332.
5
Haematological malignancies implications during the times of the COVID-19 pandemic.COVID-19大流行期间血液系统恶性肿瘤的影响
Oncol Lett. 2021 Dec;22(6):856. doi: 10.3892/ol.2021.13117. Epub 2021 Oct 29.
6
Abnormal microRNA expression in the course of hematological malignancies.血液系统恶性肿瘤病程中的微小RNA表达异常。
Cancer Manag Res. 2018 Oct 8;10:4267-4277. doi: 10.2147/CMAR.S174476. eCollection 2018.
7
Old and New Prognostic Markers in Pediatric ALL.
Indian J Hematol Blood Transfus. 2016 Jun;32(2):121-2. doi: 10.1007/s12288-016-0663-1. Epub 2016 Feb 23.
8
Changing Times for the IJHBT.《国际血液与骨髓移植杂志》的时代变迁
Indian J Hematol Blood Transfus. 2016 Mar;32(1):1-2. doi: 10.1007/s12288-015-0631-1. Epub 2015 Dec 28.
本文引用的文献
1
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.慢性淋巴细胞白血病：2015 年诊断、风险分层和治疗更新。
Am J Hematol. 2015 May;90(5):446-60. doi: 10.1002/ajh.23979.
2
Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms.评估用于预测弥漫性大B细胞淋巴瘤生存率的起源细胞亚型方法：基因表达谱和免疫组织化学算法的荟萃分析
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):460-467.e2. doi: 10.1016/j.clml.2014.05.002. Epub 2014 Jun 12.
3
Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.将多发性骨髓瘤预后的基因表达特征转化为临床实用的稳健高通量检测方法。
BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.
4
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.大多数接受伊马替尼治疗的患者达到了深度分子反应，该反应可预测生存，并且通过优化的高剂量伊马替尼更快实现：来自随机 CML-研究 IV 的结果。
J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2.
5
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.来那度胺作为 del(5q) 骨髓增生异常综合征患者的疾病修饰剂：将作用机制与临床结果联系起来。
Ann Hematol. 2014 Jan;93(1):1-11. doi: 10.1007/s00277-013-1863-5. Epub 2013 Sep 10.
6
Lessons from next-generation sequencing analysis in hematological malignancies.血液恶性肿瘤下一代测序分析的启示。
Blood Cancer J. 2013 Jul 19;3(7):e127. doi: 10.1038/bcj.2013.26.
7
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.miR-155 在单克隆 B 细胞淋巴细胞增多症个体和 B 慢性淋巴细胞白血病患者中的预后价值。
Blood. 2013 Sep 12;122(11):1891-9. doi: 10.1182/blood-2013-01-478222. Epub 2013 Jul 2.
8
Viral diagnostics in the era of digital polymerase chain reaction.数字聚合酶链反应时代的病毒诊断。
Diagn Microbiol Infect Dis. 2013 Jan;75(1):1-4. doi: 10.1016/j.diagmicrobio.2012.10.009. Epub 2012 Nov 20.
9
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.深度测序技术在急性淋巴细胞白血病微小残留病灶检测中的应用。
Blood. 2012 Dec 20;120(26):5173-80. doi: 10.1182/blood-2012-07-444042. Epub 2012 Oct 16.
10
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.欧洲白血病网络标准化系统报告成人急性髓细胞白血病细胞遗传学和分子改变的预后意义。
J Clin Oncol. 2012 Dec 20;30(36):4515-23. doi: 10.1200/JCO.2012.43.4738. Epub 2012 Sep 17.
Zotero 插件